BAKER BROS ADVISORS LLC Insider Trading Transactions
Get free email notifications about insider trading for BAKER BROS ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BAKER BROS ADVISORS LLC. BAKER BROS ADVISORS LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in ALEXION PHARMACEUTICALS INC ($ALXN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and in XOMA Corp ($XOMA) and Director in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in BELLICUM PHARMACEUTICALS, INC ($BLCM) and 10% Owner in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in Zymeworks Inc. ($ZYME) and Director in Kodiak Sciences Inc. ($KOD) and 10% Owner in Invitae Corp ($NVTA) and Director in IGM Biosciences, Inc. ($IGMS) and 10% Owner in Atreca, Inc. ($BCEL) and in Mirati Therapeutics, Inc. ($MYG) and 10% Owner in Mirati Therapeutics, Inc. ($MYG) and Director in Talis Biomedical Corp ($TLIS) and Director in Aeglea BioTherapeutics, Inc. ($AGLE) and in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and in Intellia Therapeutics, Inc. ($NTLA) and Director in BeiGene, Ltd. ($BGNE) and Director in Prelude Therapeutics Inc ($PRLD) and Director in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and in HOOKIPA Pharma Inc. ($HOOK).
Latest Insider Trading Transactions of BAKER BROS ADVISORS LLC
Sentiment: All, ACAD, AGLE, ALXN, BCEL, BGNE, BLCM, BCRX, GHDX, HOOK, IDRA, IGMS, INCY, NTLA, NVTA, KNSA, KOD, MYG, NLTX, PRLD, RYTM, SGEN, TLIS, XOMA, ZYME
Page: < prev 1 2 3 4 5 6 7 ... 11 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 57.22 | 1,267 | 72,496 | 936,807 | 935.5 K to 936.8 K (+0.14 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 58.80 | 14,402 | 846,819 | 10,198,572 | 10.2 M to 10.2 M (+0.14 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 58.80 | 1,298 | 76,321 | 935,540 | 934.2 K to 935.5 K (+0.14 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 60.77 | 8,623 | 524,043 | 10,184,170 | 10.2 M to 10.2 M (+0.08 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 60.77 | 777 | 47,220 | 934,242 | 933.5 K to 934.2 K (+0.08 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 58.54 | 6,788 | 397,393 | 10,175,547 | 10.2 M to 10.2 M (+0.07 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 58.54 | 612 | 35,829 | 933,465 | 932.9 K to 933.5 K (+0.07 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 58.39 | 7,122 | 415,826 | 10,168,759 | 10.2 M to 10.2 M (+0.07 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 58.39 | 642 | 37,484 | 932,853 | 932.2 K to 932.9 K (+0.07 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 57.62 | 3,577 | 206,108 | 10,161,637 | 10.2 M to 10.2 M (+0.04 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 57.62 | 323 | 18,611 | 932,211 | 931.9 K to 932.2 K (+0.03 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.69 | 21,301 | 1,207,513 | 10,158,060 | 10.1 M to 10.2 M (+0.21 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.69 | 1,921 | 108,898 | 931,888 | 930 K to 931.9 K (+0.21 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.62 | 5,804 | 328,631 | 10,136,759 | 10.1 M to 10.1 M (+0.06 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.62 | 523 | 29,613 | 929,967 | 929.4 K to 930 K (+0.06 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.25 | 10,121 | 569,277 | 10,130,955 | 10.1 M to 10.1 M (+0.10 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 56.25 | 912 | 51,297 | 929,444 | 928.5 K to 929.4 K (+0.10 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 55.45 | 92 | 5,102 | 10,120,834 | 10.1 M to 10.1 M (0.00 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 55.45 | 8 | 444 | 928,532 | 928.5 K to 928.5 K (0.00 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 55.77 | 1,813 | 101,117 | 10,120,742 | 10.1 M to 10.1 M (+0.02 %) |
Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 55.77 | 164 | 9,147 | 928,524 | 928.4 K to 928.5 K (+0.02 %) |
Feb 07 2020 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 40.27 | 10,000 | 402,700 | 10,000 | |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 9,765,333 | 0 | 9,765,333 | |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 1,160,148 | 0 | 1,161,048 | |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Sell | D | 0.00 | 9,765,333 | 0 | 3,107,331 | 12.9 M to 3.1 M (-75.86 %) |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Sell | D | 0.00 | 1,160,148 | 0 | 290,409 | 1.5 M to 290.4 K (-79.98 %) |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 8.40 | 2,767,505 | 23,247,042 | 12,872,664 | 10.1 M to 12.9 M (+27.39 %) |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 8.40 | 250,037 | 2,100,311 | 1,450,557 | 1.2 M to 1.5 M (+20.83 %) |
Dec 06 2019 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.00 | 1,743,993 | 80,223,678 | 10,118,929 | 8.4 M to 10.1 M (+20.82 %) |
Dec 06 2019 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.00 | 158,180 | 7,276,280 | 928,360 | 770.2 K to 928.4 K (+20.54 %) |
Dec 06 2019 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.00 | 1,743,993 | 80,223,678 | 10,118,929 | 8.4 M to 10.1 M (+20.82 %) |
Dec 06 2019 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 46.00 | 158,180 | 7,276,280 | 928,360 | 770.2 K to 928.4 K (+20.54 %) |
Oct 15 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
Oct 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 67.28 | 370 | 24,894 | 7,642,042 | 7.6 M to 7.6 M (0.00 %) |
Oct 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 67.28 | 370 | 24,894 | 1,217,279 | 1.2 M to 1.2 M (+0.03 %) |
Oct 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 67.28 | 370 | 24,894 | 244,595 | 244.2 K to 244.6 K (+0.15 %) |
Oct 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 67.28 | 370 | 24,894 | 160,223 | 159.9 K to 160.2 K (+0.23 %) |
Oct 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 67.28 | 370 | 24,894 | 165,980 | 165.6 K to 166 K (+0.22 %) |
Oct 02 2019 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 74.23 | 364 | 27,020 | 29,291,207 | 29.3 M to 29.3 M (0.00 %) |
Oct 02 2019 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 74.23 | 364 | 27,020 | 2,827,440 | 2.8 M to 2.8 M (+0.01 %) |
Sep 20 2019 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 2,081,895 | 0 | 2,081,895 | |
Sep 20 2019 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 2,081,895 | 0 | 0 | |
Sep 20 2019 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 187,942 | 0 | 187,942 | |
Sep 20 2019 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 187,942 | 0 | 0 | |
Sep 20 2019 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 16.00 | 2,883,204 | 46,131,264 | 2,883,204 | 0 to 2.9 M |
Sep 20 2019 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 16.00 | 260,796 | 4,172,736 | 260,796 | 0 to 260.8 K |
Sep 20 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 40.00 | 1,494,025 | 59,761,000 | 37,470,965 | 36 M to 37.5 M (+4.15 %) |
Sep 20 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 40.00 | 68,475 | 2,739,000 | 3,383,621 | 3.3 M to 3.4 M (+2.07 %) |
Sep 20 2019 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | X | 0.01 | 1 | 0 | 138,815 | |
Sep 20 2019 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | X | 0.01 | 1 | 0 | 8,374,936 | 8.4 M to 8.4 M (0.00 %) |
Sep 19 2019 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 16.00 | 12,100 | 193,600 | 12,100 | |
Aug 30 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Gift | G | 0.00 | 95,289 | 0 | 0 | 95.3 K to 0 (-100.00 %) |
Aug 30 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Gift | G | 0.00 | 95,289 | 0 | 0 | 95.3 K to 0 (-100.00 %) |
Aug 30 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 8,341 | 0 | 95,289 | 86.9 K to 95.3 K (+9.59 %) |
Aug 30 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 8,340 | 0 | 95,289 | 86.9 K to 95.3 K (+9.59 %) |
Aug 30 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 8,866 | 0 | 43,361 | 52.2 K to 43.4 K (-16.98 %) |
Aug 30 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 7,815 | 0 | 165,610 | 173.4 K to 165.6 K (-4.51 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.15 | 50,436 | 159,020 | 10,105,159 | 10.1 M to 10.1 M (+0.50 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.15 | 4,564 | 14,390 | 1,200,520 | 1.2 M to 1.2 M (+0.38 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.02 | 209,382 | 633,255 | 10,054,723 | 9.8 M to 10.1 M (+2.13 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.02 | 18,943 | 57,291 | 1,195,956 | 1.2 M to 1.2 M (+1.61 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.96 | 5,869 | 17,358 | 9,845,341 | 9.8 M to 9.8 M (+0.06 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.96 | 531 | 1,570 | 1,177,013 | 1.2 M to 1.2 M (+0.05 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.85 | 65,568 | 186,666 | 9,839,472 | 9.8 M to 9.8 M (+0.67 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.85 | 5,932 | 16,888 | 1,176,482 | 1.2 M to 1.2 M (+0.51 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.83 | 9,445 | 26,756 | 9,773,904 | 9.8 M to 9.8 M (+0.10 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.83 | 855 | 2,422 | 1,170,550 | 1.2 M to 1.2 M (+0.07 %) |
Jul 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 58.86 | 424 | 24,957 | 7,641,672 | 7.6 M to 7.6 M (+0.01 %) |
Jul 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 58.86 | 424 | 24,957 | 1,216,909 | 1.2 M to 1.2 M (+0.03 %) |
Jul 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 58.86 | 424 | 24,957 | 244,225 | 243.8 K to 244.2 K (+0.17 %) |
Jul 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 58.86 | 424 | 24,957 | 159,853 | 159.4 K to 159.9 K (+0.27 %) |
Jul 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 58.86 | 424 | 24,957 | 52,227 | 51.8 K to 52.2 K (+0.82 %) |
Jul 03 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 58.86 | 424 | 24,957 | 173,425 | 173 K to 173.4 K (+0.25 %) |
Jul 03 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Grant | A | 2.61 | 2,964 | 7,736 | 4,290,995 | 4.3 M to 4.3 M (+0.07 %) |
Jul 03 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Grant | A | 2.61 | 2,964 | 7,736 | 350,721 | 347.8 K to 350.7 K (+0.85 %) |
Jul 02 2019 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 84.96 | 310 | 26,338 | 29,290,843 | 29.3 M to 29.3 M (0.00 %) |
Jul 02 2019 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 84.96 | 310 | 26,338 | 2,827,076 | 2.8 M to 2.8 M (+0.01 %) |
Jun 28 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 25.24 | 30,000 | 757,200 | 30,000 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | P | 0.00 | 1,904,850 | 0 | 5,444,957 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | P | 0.00 | 95,150 | 0 | 489,234 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | C | 0.00 | 3,540,107 | 0 | 3,540,107 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | C | 0.00 | 3,540,107 | 0 | 0 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | C | 0.00 | 394,084 | 0 | 394,084 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | C | 0.00 | 394,084 | 0 | 0 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | C | 0.00 | 920,361 | 0 | 0 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | C | 0.00 | 89,878 | 0 | 0 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | C | 0.00 | 2,302,669 | 0 | 0 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | C | 0.00 | 219,852 | 0 | 0 | |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Buy | C | 0.00 | 3,223,030 | 0 | 3,223,030 | 0 to 3.2 M |
Jun 26 2019 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Buy | C | 0.00 | 309,730 | 0 | 309,730 | 0 to 309.7 K |
Jun 18 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 52.41 | 13,166 | 690,030 | 13,166 | |
Jun 18 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,910 | 0 | 7,641,248 | 7.6 M to 7.6 M (+0.03 %) |
Jun 18 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,910 | 0 | 1,216,485 | 1.2 M to 1.2 M (+0.16 %) |
Jun 18 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,910 | 0 | 243,801 | 241.9 K to 243.8 K (+0.79 %) |
Jun 18 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,910 | 0 | 159,429 | 157.5 K to 159.4 K (+1.21 %) |
Jun 18 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,910 | 0 | 51,803 | 49.9 K to 51.8 K (+3.83 %) |
Jun 18 2019 | GHDX | GENOMIC HEALTH INC | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,910 | 0 | 173,001 | 171.1 K to 173 K (+1.12 %) |
Jun 07 2019 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 220,141 | 0 | 281,190 | 61 K to 281.2 K (+360.60 %) |
Jun 07 2019 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 220,141 | 0 | 278,773 | 58.6 K to 278.8 K (+375.46 %) |
Jun 07 2019 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 692,706 | 0 | 0 | 692.7 K to 0 (-100.00 %) |
Jun 07 2019 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 1,603,238 | 0 | 2,826,766 | 4.4 M to 2.8 M (-36.19 %) |
Jun 07 2019 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 74,229 | 0 | 181,733 | 107.5 K to 181.7 K (+69.05 %) |
Jun 07 2019 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 74,229 | 0 | 181,740 | 107.5 K to 181.7 K (+69.04 %) |
Jun 07 2019 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 1,002,483 | 0 | 4,302,354 | 5.3 M to 4.3 M (-18.90 %) |
Jun 07 2019 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 14,840 | 0 | 14,840 | 0 to 14.8 K |
Jun 07 2019 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 14,840 | 0 | 14,840 | 0 to 14.8 K |
Jun 07 2019 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 200,423 | 0 | 98,980 | 299.4 K to 99 K (-66.94 %) |
Jun 07 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 31,229 | 0 | 102,876 | 71.6 K to 102.9 K (+43.59 %) |
Jun 07 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 31,229 | 0 | 102,876 | 71.6 K to 102.9 K (+43.59 %) |
Jun 07 2019 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 421,756 | 0 | 3,315,146 | 3.7 M to 3.3 M (-11.29 %) |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 0.08 | 880 | 70 | 880 | |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 0.08 | 1,660 | 133 | 1,660 | |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 0.08 | 6,256 | 500 | 6,256 | |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 0.08 | 880 | 70 | 880 | |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 0.08 | 1,660 | 133 | 1,660 | |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 0.08 | 6,256 | 500 | 6,256 | |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 0.08 | 6,009 | 481 | 0 | |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 0.08 | 11,337 | 907 | 0 | |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 0.08 | 42,724 | 3,418 | 0 | |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | J | 0.00 | 21,929 | 0 | 21,929 | 0 to 21.9 K |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | J | 0.00 | 21,929 | 0 | 21,929 | 0 to 21.9 K |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Sell | J | 0.00 | 59,267 | 0 | 0 | 59.3 K to 0 (-100.00 %) |
Jun 07 2019 | IDRA | IDERA PHARMACEUTIC ... | BAKER BROS. ADVISORS LP | 10% Owner | Sell | J | 0.00 | 178,967 | 0 | 347,757 | 526.7 K to 347.8 K (-33.98 %) |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 9.23 | 129,220 | 1,192,701 | 129,220 | |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 43,109 | 0 | 43,109 | 0 to 43.1 K |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 43,109 | 0 | 43,109 | 0 to 43.1 K |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 582,200 | 0 | 18,591 | 600.8 K to 18.6 K (-96.91 %) |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 13,516 | 0 | 20,618 | 7.1 K to 20.6 K (+190.31 %) |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 13,516 | 0 | 20,618 | 7.1 K to 20.6 K (+190.31 %) |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 182,539 | 0 | 1,028,034 | 1.2 M to 1 M (-15.08 %) |
Jun 05 2019 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 10.13 | 24,747 | 250,687 | 24,747 | |
May 31 2019 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 15.47 | 37,520 | 580,434 | 37,520 | |
May 31 2019 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 15.47 | 37,520 | 580,434 | 37,520 | |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 120.77 | 22,720 | 2,743,928 | 7,382,978 | 7.4 M to 7.4 M (-0.31 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 120.77 | 2,729 | 329,585 | 952,874 | 955.6 K to 952.9 K (-0.29 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 122.31 | 13,213 | 1,616,054 | 7,405,698 | 7.4 M to 7.4 M (-0.18 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 122.31 | 1,587 | 194,103 | 955,603 | 957.2 K to 955.6 K (-0.17 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 120.12 | 15,355 | 1,844,459 | 7,418,911 | 7.4 M to 7.4 M (-0.21 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 120.12 | 1,845 | 221,623 | 957,190 | 959 K to 957.2 K (-0.19 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 122.37 | 35,796 | 4,380,432 | 7,434,266 | 7.5 M to 7.4 M (-0.48 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 122.37 | 4,300 | 526,200 | 959,035 | 963.3 K to 959 K (-0.45 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 123.06 | 30,766 | 3,786,036 | 7,470,062 | 7.5 M to 7.5 M (-0.41 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 123.06 | 3,696 | 454,826 | 963,335 | 967 K to 963.3 K (-0.38 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 121.37 | 39,732 | 4,822,189 | 7,500,828 | 7.5 M to 7.5 M (-0.53 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 121.37 | 4,772 | 579,168 | 967,031 | 971.8 K to 967 K (-0.49 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 127.06 | 71,819 | 9,125,258 | 7,540,560 | 7.6 M to 7.5 M (-0.94 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 127.06 | 8,627 | 1,096,139 | 971,803 | 980.4 K to 971.8 K (-0.88 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 125.05 | 22,886 | 2,861,901 | 7,612,379 | 7.6 M to 7.6 M (-0.30 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 125.05 | 2,749 | 343,763 | 980,430 | 983.2 K to 980.4 K (-0.28 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 126.25 | 15,541 | 1,962,085 | 7,635,265 | 7.7 M to 7.6 M (-0.20 %) |